Assembly Biosciences Files 8-K on Material Agreement

TL;DR

ASMB filed an 8-K on Dec 30, 2024, for a material agreement & financial obligation. Watch for details.

AI Summary

Assembly Biosciences, Inc. filed an 8-K on January 3, 2025, reporting a material definitive agreement and a direct financial obligation entered into on December 30, 2024. The filing also includes financial statements and exhibits.

Why It Matters

This 8-K filing indicates significant new contractual obligations or financial arrangements for Assembly Biosciences, Inc., which could impact its financial standing and future operations.

Risk Assessment

Risk Level: medium — The filing of a material definitive agreement and financial obligation suggests significant business developments that could carry financial risks or opportunities.

Key Players & Entities

• Assembly Biosciences, Inc. (company) — Registrant
• December 30, 2024 (date) — Date of earliest event reported
• January 3, 2025 (date) — Filing date

FAQ

From the Filing

0000950170-25-001141.txt : 20250103 0000950170-25-001141.hdr.sgml : 20250103 20250103160511 ACCESSION NUMBER: 0000950170-25-001141 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20241230 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250103 DATE AS OF CHANGE: 20250103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASSEMBLY BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001426800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35005 FILM NUMBER: 25505951 BUSINESS ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (833) 409-4583 MAIL ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: VENTRUS BIOSCIENCES INC DATE OF NAME CHANGE: 20080211 8-K 1 asmb-20241230.htm 8-K 8-K 0001426800 false 0001426800 2024-12-30 2024-12-30       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2024 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)       Two Tower Place , 7th Floor , South San Francisco , California 94080 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: (833) 509-4583 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001   ASMB   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐         Item 1.01 Entry into a Material Definitive Agreement. On December 30, 2024, Assembly Biosciences, Inc. (the "Company") and Arsenal Biosciences, Inc. (the "Sublessor") entered into a First Amendment to Sublease to amend the Company’s sublease of approximately 20,000 square feet of office and laboratory space (the “Premises”) located at 2 Tower Place, 7th Floor, South San Francisco, California (the "Amendment"). The Amendment extends the term of the sublease through Septem